http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020261442-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d0d369c6868594442179670e0865acdc |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-662 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4748 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-225 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-222 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-225 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-222 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4748 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-662 |
| filingDate | 2019-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2299e03fd0e1e1edbe3cc22978b803a |
| publicationDate | 2020-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2020261442-A1 |
| titleOfInvention | Targeted drug rescue with novel compositions, combinations, and methods thereof |
| abstract | pharmaceutically acceptable salts thereof, enantiomers thereof, metabolites thereof, derivatives thereof, prodrugs thereof, acid addition salts thereof, pharmaceutically acceptable salts thereof, or N-oxides thereof; or a combination thereof, processes and intermediates for preparation thereof, compositions thereof, and uses thereof, are provided. Pharmaceutical compositions comprising a compound of Formula I, or enantiomers thereof, metabolites thereof, derivatives thereof, prodrugs thereof, acid addition salts thereof, pharmaceutically acceptable salts thereof, or N-oxides thereof; or a combination thereof, wherein the compound is double and/or triple agent or ligand for CYP2D6, 5-HT2A, and/or 5HT2C receptors, and/or acetylcholinesterase; and methods comprising co-administering a compound of Formula I and an N-Methyl-d-Aspartate (NMDA) receptor antagonist to a subject in need thereof, and dosage forms, drug delivery systems, methods of treatment thereof. The compositions contain one of more ligands for CYP2D6, 5-HT2A, 5HT2C, and N-Methyl-d-Aspartate (NMDA) receptors, and acetylcholinesterase. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102489860-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023014431-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11478467-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023033557-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11426367-B2 |
| priorityDate | 2016-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 3825.